CN114480441A - 一段核苷酸序列及其表达重组蛋白纳米颗粒在犬瘟热病毒疫苗的应用 - Google Patents
一段核苷酸序列及其表达重组蛋白纳米颗粒在犬瘟热病毒疫苗的应用 Download PDFInfo
- Publication number
- CN114480441A CN114480441A CN202111569440.5A CN202111569440A CN114480441A CN 114480441 A CN114480441 A CN 114480441A CN 202111569440 A CN202111569440 A CN 202111569440A CN 114480441 A CN114480441 A CN 114480441A
- Authority
- CN
- China
- Prior art keywords
- delta
- nucleotide sequence
- recombinant
- protein
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 49
- 241000712083 Canine morbillivirus Species 0.000 title claims abstract description 41
- 229960005486 vaccine Drugs 0.000 title claims abstract description 32
- 239000002773 nucleotide Substances 0.000 title claims abstract description 23
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 23
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims description 14
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 43
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 26
- 108050000784 Ferritin Proteins 0.000 claims abstract description 22
- 239000013598 vector Substances 0.000 claims abstract description 12
- 239000013604 expression vector Substances 0.000 claims abstract description 9
- 239000012634 fragment Substances 0.000 claims abstract description 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 19
- 102000008857 Ferritin Human genes 0.000 claims description 16
- 238000008416 Ferritin Methods 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 241001052560 Thallis Species 0.000 claims description 9
- 238000001976 enzyme digestion Methods 0.000 claims description 8
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 8
- 238000010276 construction Methods 0.000 claims description 7
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- 239000007983 Tris buffer Substances 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- 102000003960 Ligases Human genes 0.000 claims description 4
- 108090000364 Ligases Proteins 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000009465 prokaryotic expression Effects 0.000 claims description 4
- 108091008146 restriction endonucleases Proteins 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000010414 supernatant solution Substances 0.000 claims description 4
- 239000012880 LB liquid culture medium Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 2
- 239000012460 protein solution Substances 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 238000001261 affinity purification Methods 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 238000011161 development Methods 0.000 abstract description 3
- 229940023143 protein vaccine Drugs 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 description 10
- 101710169105 Minor spike protein Proteins 0.000 description 10
- 101710081079 Minor spike protein H Proteins 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 208000000655 Distemper Diseases 0.000 description 8
- 208000014058 canine distemper Diseases 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000002238 attenuated effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 238000002296 dynamic light scattering Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000001338 self-assembly Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 241000282465 Canis Species 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 241000428199 Mustelinae Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000283216 Phocidae Species 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 241000282335 Procyon Species 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 108010055837 phosphocarrier protein HPr Proteins 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- -1 salt ion Chemical class 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111569440.5A CN114480441B (zh) | 2021-12-21 | 2021-12-21 | 一段核苷酸序列及其表达重组蛋白纳米颗粒在犬瘟热病毒疫苗的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111569440.5A CN114480441B (zh) | 2021-12-21 | 2021-12-21 | 一段核苷酸序列及其表达重组蛋白纳米颗粒在犬瘟热病毒疫苗的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114480441A true CN114480441A (zh) | 2022-05-13 |
CN114480441B CN114480441B (zh) | 2023-03-21 |
Family
ID=81494888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111569440.5A Active CN114480441B (zh) | 2021-12-21 | 2021-12-21 | 一段核苷酸序列及其表达重组蛋白纳米颗粒在犬瘟热病毒疫苗的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114480441B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117510596A (zh) * | 2023-11-13 | 2024-02-06 | 中山迈托姆生物技术有限公司 | 一种大肠杆菌高密度表达犬瘟热抗原的发酵工艺及其应用 |
CN117653723A (zh) * | 2023-12-01 | 2024-03-08 | 中山迈托姆生物技术有限公司 | 一种重组犬瘟热病毒疫苗的纯化方法及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010088552A1 (en) * | 2009-01-30 | 2010-08-05 | The Board Of Regents For Oklahoma State University | Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs |
CN102971010A (zh) * | 2010-02-26 | 2013-03-13 | 梅里亚有限公司 | 重组cdv组合物和其使用 |
CN110951699A (zh) * | 2019-12-17 | 2020-04-03 | 长春西诺生物科技有限公司 | 表达犬瘟热病毒结构蛋白的重组狂犬病病毒及其应用 |
CN111991556A (zh) * | 2020-10-29 | 2020-11-27 | 中山大学 | SARS-CoV-2 RBD共轭纳米颗粒疫苗 |
-
2021
- 2021-12-21 CN CN202111569440.5A patent/CN114480441B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010088552A1 (en) * | 2009-01-30 | 2010-08-05 | The Board Of Regents For Oklahoma State University | Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs |
CN102459578A (zh) * | 2009-01-30 | 2012-05-16 | 俄克拉荷马州大学评议会 | 基于在北美狗中循环的犬瘟热病毒的免疫原性组合物、疫苗和诊断方法 |
CN102971010A (zh) * | 2010-02-26 | 2013-03-13 | 梅里亚有限公司 | 重组cdv组合物和其使用 |
CN110951699A (zh) * | 2019-12-17 | 2020-04-03 | 长春西诺生物科技有限公司 | 表达犬瘟热病毒结构蛋白的重组狂犬病病毒及其应用 |
CN111991556A (zh) * | 2020-10-29 | 2020-11-27 | 中山大学 | SARS-CoV-2 RBD共轭纳米颗粒疫苗 |
Non-Patent Citations (4)
Title |
---|
BI Z等: "Development and characterization of neutralizing monoclonal antibodies against canine distemper virus hemagglutinin protein", 《MICROBIOL IMMUNOL》 * |
WANG B等: "Self-assembling ferritin nanoparticles coupled with linear sequences from canine distemper virus haemagglutinin protein elicit robust immune responses", 《 J NANOBIOTECHNOLOGY.》 * |
施鹏飞: "犬瘟热病毒H蛋白和犬细小病毒VP2蛋白单克隆抗体的制备及抗原表位的筛选", 《中国优秀博硕士学位论文全文数据库(硕士)基础科学辑》 * |
易立等: "犬瘟热病毒H基因5'端的表达纯化及抗原性分析", 《特产研究》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117510596A (zh) * | 2023-11-13 | 2024-02-06 | 中山迈托姆生物技术有限公司 | 一种大肠杆菌高密度表达犬瘟热抗原的发酵工艺及其应用 |
CN117653723A (zh) * | 2023-12-01 | 2024-03-08 | 中山迈托姆生物技术有限公司 | 一种重组犬瘟热病毒疫苗的纯化方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114480441B (zh) | 2023-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114480441B (zh) | 一段核苷酸序列及其表达重组蛋白纳米颗粒在犬瘟热病毒疫苗的应用 | |
CN112089831B (zh) | 重组新型冠状病毒亚单位疫苗的制备方法 | |
CN115850396B (zh) | 一种rsv纳米颗粒疫苗及其制备方法与应用 | |
CN103305542B (zh) | 一种重组噬菌体双表达载体及应用 | |
CN106478783B (zh) | 一种猪圆环病毒ii型基因工程亚单位疫苗及其应用 | |
CN106636015B (zh) | 一种嵌合型新城疫病毒样颗粒的制备方法 | |
CN106636016B (zh) | 一种通过正负电荷引入辅助病毒样颗粒自组装的方法和应用 | |
CN111187781B (zh) | 一种优化后的猪圆环病毒3型衣壳蛋白基因及其在制备病毒样颗粒中的应用 | |
CN111875676A (zh) | 非洲猪瘟病毒免疫原的p49突变蛋白、重组载体、大肠杆菌基因工程菌及制备方法和应用 | |
CN111548395A (zh) | 一种口蹄疫病毒二价多表位重组病毒样颗粒及其应用 | |
CN113603754B (zh) | 一种水禽h5n8亚型流感病毒ha重组蛋白及其制备方法与应用 | |
CN105969786B (zh) | 一种表达ms2噬菌体衣壳蛋白和成熟酶的质粒 | |
CN110981968A (zh) | 含有狂犬病病毒g蛋白的融合蛋白及其制备方法、应用和疫苗 | |
CN106905434B (zh) | 一种包含蹄蝠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用 | |
CN113462699A (zh) | 一种利用大肠杆菌表达猫细小vp2蛋白自主组装病毒样颗粒的制备 | |
CN107058363B (zh) | 基于淀粉样蛋白实现小分子肽类高效分泌表达的方法及其应用 | |
CN112679586A (zh) | H5、h7亚型禽流感病毒基因工程亚单位疫苗及其制备方法与应用 | |
CN111378017B (zh) | 小反刍兽疫病毒的亚单位f蛋白及其制备方法和应用 | |
CN110846326A (zh) | 一种貉细小病毒vp2基因、表达载体、重组菌、制备vp2蛋白的方法和组装方法 | |
WO2023025287A1 (zh) | 新型冠状病毒免疫原性物质、其制备方法和应用 | |
CN114703204A (zh) | 猫细小病毒vp2蛋白及所得自主组装病毒样颗粒 | |
CN116059338A (zh) | 一种犬瘟热病毒和犬细小病毒的二联亚单位疫苗及其制备方法和应用 | |
CN106986943B (zh) | 一种包含北极地松鼠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用 | |
CN115028744B (zh) | 一种口蹄疫病毒vp1嵌合纳米颗粒及其制备方法和应用 | |
CN111732667B (zh) | 小反刍兽疫病毒基因工程亚单位疫苗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231115 Address after: Room 13-044, 13th Floor, No.1 Jiankang Road, Torch Development Zone, Zhongshan City, Guangdong Province, 528436 Patentee after: Zhongshan Metom Biotechnology Co.,Ltd. Address before: 130000 rooms 101 and 401, building E11, industrial phase II C3 project, northeast Lake Science and Technology Park, south of bing37 road and bing18 street, Beihu science and Technology Development Zone, Changchun City, Jilin Province Patentee before: CHANGCHUN WEISHI DETECTION TECHNOLOGY SERVICE Co.,Ltd. |
|
TR01 | Transfer of patent right |